The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
Open accessAbstract
The term thrombotic microangiopathy (TMA) defines a lesion of vessel wall thickening (mainly arterioles or capillaries), intraluminal platelet thrombosis, and partial or complete obstruction of the vessel lumina. Depending on whether renal or brain lesions prevail, two pathologically indistinguishable but somehow clinically different entities have been described: the hemolytic uremic syndrome (HUS) and the thrombotic thrombocytopenic purpura (TTP). Injury to the endothelial cell is the central and likely inciting factor in the sequence of events leading to TMA. Loss of physiological thromboresistance, leukocyte adhesion to damaged endothelium, complement consumption, abnormal von Willebrand factor release and fragmentation, and increased vascular shear stress may then sustain and amplify the microangiopathic process. Intrinsic abnormalities of the complement system and of the von Willebrand factor pathway may account for a genetic predisposition to the disease that may play a paramount role in particular in familial and recurrent forms. Outcome is usually good in childhood, Shiga toxin-associated HUS, whereas renal and neurological sequelae are more frequently reported in adult, atypical, and familial forms of HUS and in TTP. Plasma infusion or exchange is the only treatment of proven efficacy. Bilateral nephrectomy and splenectomy may serve as rescue therapies in very selected cases of plasma resistant HUS or recurrent TTP, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hemorrhagic Colitis Associated with a Rare Escherichia coli Serotype
Riley, L. W., Remis, R. S., Helgerson, S. D., McGee, H. B., Wells, J. G., Davis, B. R., Hebert, R. J., Olcott, E. S., Johnson, L. M., Hargrett, N. T., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303243081203 · Cited by 2,668
Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., & Spasoff, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250604 · Cited by 1,920
Griffin, P. M., & Tauxe, R. V. (1991) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036079 · Cited by 1,807
Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
Tsai, H.-M., & Lian, E. C.-Y. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392203 · Cited by 1,760
Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P. A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392202 · Cited by 1,657
Self-citationVero response to a cytotoxin of Escherichia coli
Konowalchuk, J., Speirs, J. I., & Stavric, S. (1977) · Infection and Immunity · doi:10.1128/iai.18.3.775-779.1977 · Cited by 1,149
Wong, C. S., Jelacic, S., Habeeb, R. L., Watkins, S. L., & Tarr, P. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422601 · Cited by 1,094
Karmali, M., Petric, M., Steele, B., & Lim, C. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91795-6 · Cited by 1,035
Mead, P. S., & Griffin, P. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01267-7 · Cited by 1,027
Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel
Bennett, C. L., Connors, J. M., Carwile, J. M., Moake, J. L., Bell, W. R., Tarantolo, S. R., McCarthy, L. J., Sarode, R., Hatfield, A. J., Feldman, M. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422402 · Cited by 643
Cited by
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Self-citationCaprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Self-citationSzczepiorkowski, Z. M., Winters, J. L., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R., Schwartz, J., Weinstein, R., & Shaz, B. H. (2010) · Journal of Clinical Apheresis · doi:10.1002/jca.20240 · Cited by 508
Renal toxicity of therapeutic drugs
John, R., & Herzenberg, A. M. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.058271 · Cited by 93
Metadata
- Authors
- Ruggenenti, P., Noris, M., & Remuzzi, G.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2001-09
- Volume
- 60
- Issue
- 3
- Pages
- 831-846
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2031360287
- Cited by
- 489
- References
- 44
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. https://app.cochat.ai/papers/10.1046/j.1523-1755.2001.060003831.x
- The paper
- Ruggenenti, P., Noris, M., & Remuzzi, G. (2001). Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International. https://doi.org/10.1046/j.1523-1755.2001.060003831.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.